



**Institutional Biosafety Committee (IBC)**  
**Zoom Meeting Minutes**  
18 May 2026  
9:00-11:00am (Mountain Time)

**Attendance:**

**Voting IBC Members:**

- Dr. [REDACTED] (EC)
- Dr. [REDACTED] (HD)
- Dr. [REDACTED] (PD)
- Dr. [REDACTED] (MF)
- Dr. [REDACTED] (LH)
- Dr. [REDACTED] (BH)
- [REDACTED] (EK)
- Dr. [REDACTED] (AL)\*\*
- Dr. [REDACTED] (JL)
- Dr. [REDACTED] (CM)
- Dr. [REDACTED] (Co-chair) (TM)\*
- [REDACTED] (JR)
- Dr. [REDACTED] (MV)
- [REDACTED] (ZJW)
- [REDACTED] (ZW)

**Non-voting IBC Members/Guests:**

- [REDACTED] (AA)
- [REDACTED] (QB)
- [REDACTED] (JW)

**I. Call to Order:** 9:00am (Mountain Time)

**II. Conflict of Interest:**

- All present IBC members were reminded that no member of an IBC may be involved (except to provide information requested by the IBC) in the review of approval of a project in which he/she/they have been or expect(s) to have a conflict of interest—including financial interests, personal relationships, or involvement in the research. Any committee member with a conflict of interest shall abstain from the vote.

**III. Review and Approval of Previous Minutes:** 27 April 2026

The minutes were reviewed and approved by the IBC.

Approved = 15

Opposed = 0

Abstained = 0

**IV. IBC Administrative Business:**

**A. IBC Administrative Changes:** None

**B. Protocol Closures:**

- i. [REDACTED] - # 1245
- ii. [REDACTED] - # 24-2596

**C. Protocol Transfers:** None

**Recombinant and/or Synthetic Nucleic Acid Molecules Research Applications Review:**

During the review, the IBC assessed the containment levels in addition to the facilities, procedures, practices, training, and expertise of the laboratory personnel involved in recombinant and/or synthetic nucleic acid molecules research. Additionally, the IBC reviewed agent characteristics, types of manipulations planned, sources of the inserted nucleic acid sequences,



the nature of the inserted nucleic acid sequences, and whether an attempt will be made to obtain expression of a foreign gene, and, if so, the protein that will be produced. The Principal Investigator must determine the applicable section(s) of the *NIH Guidelines*.

**V. New Business:**

1. **Environmental Health and Safety Office Updates:** None
2. **Biosafety Office Updates:**
  - i. BH updated the IBC on the status of the new IBC protocol form and called for test group volunteers.

**VI. Clinical Trial (Human Gene Transfer) Amendments and Notices:**

1. Monge Urrea, Jorge - # 24-2523: *A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma*
2. McCandless, Shawn - # 23-2307: *A Phase I/II First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of a Single Intravenous (IV) Administration of ECUR-506 in Males Less than 9 Months of Age with Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency*
3. Piquet, Amanda - # 24-1330: *A Phase 2 Open-Label, Single-Arm, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Treatment Refractory Stiff Person Syndrome (KYSA-8)*
4. Lieu, Christopher - # 22-0697: *A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART In Subjects with Relapsed or Refractory Metastatic Colorectal Cancer (CARAPIA-1 Study)*
5. Patel, Sapna - # 25-0004: *A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma*
6. Leal, Alexis - # 23-2048: *Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors.*
7. Angelos, Mathew - # 22-0054: *First-in-Human, Open-Label, Safety, Tolerability, Dose Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-401, a recombinant adeno-associated virus serotype 9 (AAV9) containing Plakophilin-2 (PKP2) transgene, in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)*
8. Schenk, Erin - # 24-2314: *A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)*

**VII. Clinical Trial (Human Gene Transfer) Protocol Reviews: None**

**VIII. New Laboratory Protocol Reviews:**

1. [REDACTED] - # 1754: **Investigation of the impact of neurotropic infections as a risk factor for neurodegenerative disease.**  
Biosafety level(s): BSL-2, BSL-2+  
NIH Section(s): III-D-1, III-D-2, III-D-3, III-E-1, III-F  
Approved = 15  
Opposed = 0  
Abstained = 0



The IBC protocol presented was approved with the recommendation for modifications required to address updating biomaterial, rDNA, and micro/infectious agents sections of the IBC protocol form, clarifying discrepancies throughout the IBC protocol form, updating PPE and engineering control details, and providing a biosafety manual.

2. [REDACTED] - # 1771: **Characterizing and targeting intratumor heterogeneity in brain tumors**

Biosafety level(s): BSL-2, ABSL-2

NIH Section(s): III-D-4, III-D-2, III-D-1, III-F

Approved = 13

Opposed = 0

Abstained = 0

The IBC protocol presented was deferred for further review at a later date with sending current reviewer comments to the laboratory to revise the application.

IX. **De Novo Laboratory Protocol Reviews:**

1. [REDACTED] - # 1060: **Role of intestinal microbiota in influencing host physiology**

Biosafety level(s): BSL-2, ABSL-2

NIH Section(s): III-D-4, III-E-3, III-F

Approved = 15

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including clarifying “taking out of containment” language and updating protocol form checkboxes.

\*TM left the meeting at 9:23am.

2. [REDACTED] - # 1154: **The effects of advanced age and alcohol intoxication on inflammatory responses after injury and/or infection**

Biosafety level(s): BSL-1, BSL-2, ABSL-1, ABSL-2

NIH Section(s): III-D-4, III-F

Approved = 14

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including updating protocol form checkboxes, adding micro/infectious procedures, updating BSC certification and IRB details, and removing outdated application attachments.

3. [REDACTED] - # 1184: **Molecular and Pharmacological Dissection of Oncogenic Signal Pathways**

Biosafety level(s): BSL-1, BSL-2, ABSL-1

NIH Section(s): III-D-1, III-D-2, III-D-3, III-E-1, III-F

Approved = 14

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including updating protocol form checkboxes, vector details, biomaterial and downstream procedure details, and clarifying use of human primary materials.



4. [REDACTED] - # 1487: **Mechanisms of early lung cancer development and chemoprevention.**  
Biosafety level(s): BSL-1, BSL-2, ABSL-1  
NIH Section(s): III-D-1, III-D-2, III-F  
Approved = 14  
Opposed = 0  
Abstained = 0  
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating the associated IACUC protocol's expiration date details.
  
5. [REDACTED] - # 1093: **Pathogenesis and treatment of pulmonary vascular disease or Redox Regulated Signaling in the Lung and Pulmonary Vasculature**  
Biosafety level(s): BSL-2, ABSL-2  
NIH Section(s): III-D-1, III-D-2, III-D-4  
Approved = 14  
Opposed = 0  
Abstained = 0  
The IBC protocol presented was approved with the recommendation for modifications required to address updating research narrative, nanoparticle, rDNA, biomaterial, and engineering control details and protocol form checkboxes, as well as updating language for signs and symptoms for micro/infectious agents.
  
6. [REDACTED] - # 1429: **Regulation of immune response, metabolism and cancer**  
Biosafety level(s): BSL-2, ABSL-2  
NIH Section(s): III-D-1, III-D-4, III-F  
Approved = 14  
Opposed = 0  
Abstained = 0  
The IBC protocol presented was approved with the recommendation for modifications required to address updating protocol form checkboxes, clarifying use of CAR-T cells, and updating language for signs and symptoms for micro/infectious agents.
  
7. [REDACTED] - # 1277: **Metabolic changes in acute lung injury in its influence on inflammation**  
Biosafety level(s): BSL-2, ABSL-2  
NIH Section(s): III-D-3, III-D-4, III-E-1, III-E-3, III-F  
Approved = 14  
Opposed = 0  
Abstained = 0  
The IBC protocol presented was approved with the recommendation to address minor administrative items including clarifying use of human plasma, updating the listed expiration date for the associated IACUC protocol, and updating protocol form checkboxes.

\*\*AL left the meeting at 10:06am.

**X. Significant Amendment Reviews for Laboratory Protocols:**

1. [REDACTED] - # 1670: **Generation of genetically modified mice using molecular tools**  
Biosafety level(s): BSL-2, ABSL-1



NIH Section(s): III-D-4, III-D-2, III-D-1

Approved = 13

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including updating NIH Guidelines checkboxes and listing BSC details for corresponding procedures.

**XI. Exempt Protocols – New/Renewal:**

1. [REDACTED] - # 1228: *Environmental and occupational toxicant effects in lung: carcinogens/tumor promoters and pulmonary inflammagens.*
2. [REDACTED] - # 1124: *Endogenous mediators of kidney protection: Acetylcholine, acetylcholine receptors, and A2A adenosine receptors.*
3. [REDACTED] - # 1493: *Intercellular communication and protein spatiotemporal dynamics in human induced pluripotent stem cell models*

**XII. Exempt Protocol Amendments:**

1. [REDACTED] - # 1406: *Microbial community characterization of chemically-impacted ecosystems, e.g., water, soil, and waste streams such as acid mine drainage Project 2. Analysis of elk herd genetics via an examination of elk fecal material*
2. [REDACTED] - # 1065: *Development and Homeostasis of innate T cells.*

**XIII. Additional Business:** None

**XIV. Next Meeting Scheduled:** 22 June 2026, 9:00am (Mountain Time)

**XV. Adjournment:** 10:12 am (Mountain Time)